Quest Diagnostics Incorporated (DGX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $28.56B
Last updated: Nov 17, 2026 at 11:03 AM ET
Quest Diagnostics Incorporated (DGX) Earnings: Report Dates and Results
Quest Diagnostics (DGX) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Quest Diagnostics reported EPS of $3.00, above the $2.85 estimate. It beat the EPS estimate in each of the last 31 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DGX has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 12.0% above the $2.42 reported for the quarter ended Dec 31, 2025.
DGX Earnings Call
The latest DGX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, DGX beat 37, missed 2 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.10B, up 9.9% from $2.82B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.00 | $2.85 | $2.82 - $2.94 | +5.26% | Beat | +15.4% | 14 | 1 up, 0 down | Oct 22, 2026 | $3.10B |
| Jun 30, 2026 | $3.12 | $2.81 | $2.75 - $2.91 | +11.03% | Beat | +19.1% | 15 | 2 up, 10 down | Jul 23, 2026 | $3.04B |
| Mar 31, 2026 | $2.50 | $2.37 | $2.25 - $2.47 | +5.49% | Beat | +13.1% | 14 | 5 up, 4 down | Apr 21, 2026 | $2.90B |
| Dec 31, 2025 | $2.42 | $2.36 | $2.28 - $2.41 | +2.54% | Beat | +8.5% | 14 | 2 up, 0 down | Feb 10, 2026 | $2.81B |
| Sep 30, 2025 | $2.60 | $2.50 | $2.46 - $2.57 | +4.00% | Beat | +13.0% | 15 | 2 up, 3 down | Oct 21, 2025 | $2.82B |
| Jun 30, 2025 | $2.62 | $2.57 | $2.54 - $2.69 | +1.95% | Beat | +11.5% | 14 | 9 up, 4 down | Jul 22, 2025 | $2.76B |
| Mar 31, 2025 | $2.21 | $2.15 | $2.08 - $2.24 | +2.79% | Beat | +8.3% | 14 | 0 up, 9 down | Apr 22, 2025 | $2.65B |
| Dec 31, 2024 | $2.23 | $2.18 | $2.13 - $2.22 | +2.29% | Beat | +3.7% | 15 | 0 up, 2 down | Jan 30, 2025 | $2.62B |
| Sep 30, 2024 | $2.30 | $2.26 | $2.22 - $2.32 | +1.77% | Beat | +3.6% | 16 | 0 up, 5 down | Oct 22, 2024 | $2.49B |
| Jun 30, 2024 | $2.35 | $2.33 | $2.26 - $2.39 | +0.86% | Beat | +2.2% | 15 | 2 up, 0 down | Jul 23, 2024 | $2.40B |
| Mar 31, 2024 | $2.04 | $1.86 | $1.82 - $1.90 | +9.68% | Beat | 0.0% | 16 | 2 up, 0 down | Apr 23, 2024 | $2.37B |
| Dec 31, 2023 | $2.15 | $2.11 | $1.83 - $2.18 | +1.90% | Beat | +8.6% | 15 | 1 up, 0 down | Feb 1, 2024 | $2.29B |
| Sep 30, 2023 | $2.22 | $2.19 | $2.09 - $2.25 | +1.37% | Beat | -5.9% | 15 | 0 up, 1 down | Oct 24, 2023 | $2.29B |
| Jun 30, 2023 | $2.30 | $2.26 | $2.11 - $2.36 | +1.77% | Beat | -2.5% | 16 | 3 up, 1 down | Jul 26, 2023 | $2.34B |
| Mar 31, 2023 | $2.04 | $1.97 | $1.92 - $2.07 | +3.55% | Beat | -36.6% | 14 | 0 up, 1 down | Apr 27, 2023 | $2.33B |
| Dec 31, 2022 | $1.98 | $1.90 | $1.85 - $1.96 | +4.21% | Beat | -40.5% | 15 | 4 up, 0 down | Feb 2, 2023 | $2.33B |
| Sep 30, 2022 | $2.36 | $2.19 | $2.06 - $2.34 | +7.76% | Beat | -40.4% | 14 | 3 up, 1 down | Oct 20, 2022 | $2.49B |
| Jun 30, 2022 | $2.36 | $2.27 | $2.13 - $2.71 | +3.96% | Beat | -25.8% | 14 | 4 up, 0 down | Jul 21, 2022 | $2.45B |
| Mar 31, 2022 | $3.22 | $3.00 | $2.62 - $3.60 | +7.33% | Beat | -14.4% | 14 | 2 up, 2 down | Apr 21, 2022 | $2.61B |
| Dec 31, 2021 | $3.33 | $3.21 | $2.75 - $3.52 | +3.74% | Beat | -25.7% | 15 | 6 up, 1 down | Feb 3, 2022 | $2.74B |
| Sep 30, 2021 | $3.96 | $3.06 | $2.07 - $3.76 | +29.41% | Beat | -8.1% | 15 | N/A | Oct 21, 2021 | $2.77B |
| Jun 30, 2021 | $3.18 | $2.86 | $2.61 - $2.99 | +11.19% | Beat | +123.9% | 14 | N/A | Jul 22, 2021 | $2.55B |
| Mar 31, 2021 | $3.76 | $3.73 | $3.41 - $4.09 | +0.80% | Beat | +300.0% | 15 | N/A | Apr 22, 2021 | $2.72B |
| Dec 31, 2020 | $4.48 | $4.24 | $3.75 - $4.65 | +5.66% | Beat | +168.3% | 14 | N/A | Feb 4, 2021 | $3.00B |
| Sep 30, 2020 | $4.31 | $3.73 | $3.14 - $4.25 | +15.55% | Beat | +144.9% | 15 | N/A | Oct 22, 2020 | $2.79B |
| Jun 30, 2020 | $1.42 | $1.25 | N/A | +13.60% | Beat | -17.9% | 7 | N/A | Jul 23, 2020 | $1.83B |
| Mar 31, 2020 | $0.94 | $0.88 | $0.31 - $1.49 | +6.82% | Beat | -32.9% | 13 | N/A | Apr 22, 2020 | $1.82B |
| Dec 31, 2019 | $1.67 | $1.60 | $1.58 - $1.65 | +4.38% | Beat | +22.8% | 16 | N/A | Jan 30, 2020 | $1.93B |
| Sep 30, 2019 | $1.76 | $1.71 | $1.65 - $1.79 | +2.92% | Beat | +4.8% | 16 | N/A | Oct 22, 2019 | $1.96B |
| Jun 30, 2019 | $1.73 | $1.68 | $1.62 - $1.73 | +2.98% | Beat | -1.1% | 18 | N/A | Jul 23, 2019 | $1.95B |
| Mar 31, 2019 | $1.40 | $1.38 | $1.30 - $1.39 | +1.45% | Beat | -7.9% | 18 | N/A | Apr 23, 2019 | $1.89B |
| Dec 31, 2018 | $1.36 | $1.37 | $1.29 - $1.40 | -0.73% | Miss | -2.9% | 17 | N/A | Feb 14, 2019 | $1.84B |
| Sep 30, 2018 | $1.68 | $1.68 | $1.63 - $1.74 | 0.00% | In line | +20.9% | 17 | N/A | Oct 23, 2018 | $1.89B |
| Jun 30, 2018 | $1.75 | $1.76 | $1.70 - $1.78 | -0.57% | Miss | +12.9% | 16 | N/A | Jul 24, 2018 | $1.92B |
| Mar 31, 2018 | $1.52 | $1.50 | $1.41 - $1.58 | +1.33% | Beat | +14.3% | 17 | N/A | Apr 19, 2018 | $1.88B |
| Dec 31, 2017 | $1.40 | $1.37 | $1.34 - $1.55 | +2.19% | Beat | +6.9% | 18 | N/A | Feb 1, 2018 | $1.86B |
| Sep 30, 2017 | $1.39 | $1.36 | $1.28 - $1.45 | +2.21% | Beat | +1.5% | 17 | N/A | Oct 19, 2017 | $1.86B |
| Jun 30, 2017 | $1.55 | $1.42 | $1.38 - $1.51 | +9.15% | Beat | +15.7% | 20 | N/A | Jul 25, 2017 | $1.86B |
| Mar 31, 2017 | $1.33 | $1.18 | N/A | +12.71% | Beat | +18.7% | N/A | N/A | Apr 20, 2017 | $1.82B |
| Dec 31, 2016 | $1.31 | $1.27 | N/A | +3.15% | Beat | +10.1% | N/A | N/A | Jan 26, 2017 | $1.56B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $9.85, up 10.4% from the year before. It was $5.14 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $9.85 | +10.4% |
| Dec 31, 2024 | $8.92 | +2.4% |
| Dec 31, 2023 | $8.71 | -12.2% |
| Dec 31, 2022 | $9.92 | -30.3% |
| Dec 31, 2021 | $14.23 | +27.6% |
| Dec 31, 2020 | $11.15 | +70.0% |
| Dec 31, 2019 | $6.56 | +4.0% |
| Dec 31, 2018 | $6.31 | +11.3% |
| Dec 31, 2017 | $5.67 | +10.3% |
| Dec 31, 2016 | $5.14 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,264 | 17 | |
| 2026Q2 | Jun 30, 2026 | 7,479 | 15 | |
| 2026Q1 | Mar 31, 2026 | 7,634 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,422 | 15 | |
| 2025Q3 | Sep 30, 2025 | 6,765 | 17 | |
| 2025Q2 | Jun 30, 2025 | 6,799 | 17 | |
| 2025Q1 | Mar 31, 2025 | 7,238 | 16 | |
| 2024Q4 | Dec 31, 2024 | 7,696 | 15 |
2026Q3 Earnings Call
Opening remarks
Dominique Joshi Vice President of Investor Relations Thank you, and good morning. I am joined by Jim Davis, our Chairman, Chief Executive Officer, and President, and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and we will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long-term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth, are compound annual growth rates. Now here is Jim.
Jim Davis Chairman, CEO, and President Thanks, Dominique, and welcome everyone to this morning's call. I am excited to discuss our strong performance in the third quarter and how our strategy to connect people and providers to innovative testing and actionable insights is illuminating paths for better health and generating shareholder value. We grew revenues 10% and adjusted earnings per share over 15% in the quarter on continued strength across our physician, hospital, and consumer channels, complemented by productivity gains from automation and AI. Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population, as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are again raising our guidance for revenues and earnings per share for the full year. Now I'll provide more detail on how we executed our strategy across our key customer channels and operations during the quarter. Quest operates at the center of healthcare. We deliver solutions that make testing simpler and smarter for our core clinical customers, physicians, and hospitals, as well as for customers in the higher-growth areas of consumer health, life sciences, and data analytics. In the physician channel, we delivered high single-digit revenue growth in the third quarter on strong commercial execution and broad demand across our test portfolio. We also continued to grow in geographies where we've expanded our access in recent years through health plan collaborations and outreach acquisitions. We are excited about our collaborations with Fresenius Medical Care and opportunities to serve new customers based on our growing kidney diagnostics expertise.
Frequently Asked Questions About DGX
When is Quest Diagnostics's next earnings date?
Quest Diagnostics's next earnings report is expected for Feb 8, 2027.
Did DGX beat earnings estimates last quarter?
Yes. Quest Diagnostics reported EPS of $3.00 for the quarter ended Sep 30, 2026, above the $2.85 estimate, a 5.26% surprise.
What EPS do analysts expect from DGX next quarter?
The consensus EPS estimate for Quest Diagnostics for the quarter ending Dec 31, 2026 is $2.71 from 17 analysts, with estimates from $2.56 to $2.88.
How often does DGX beat earnings estimates?
Quest Diagnostics beat the EPS estimate in each of the last 31 quarters, with an average surprise of +5.74%.
DGX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts